Organon and JD Health Launch "Comprehensive White Paper on Male Androgenetic Alopecia" to Address Unmet Patient Needs
In recent years, hair loss has garnered significant attention, with related topics frequently trending online. According to the “Guidelines for the Diagnosis and Treatment of Androgenetic Alopecia in China,” androgenetic alopecia (abbreviated as “AGA”) is the most common type among various forms of hair loss.1. In China, the prevalence of androgenetic alopecia in men is approximately 21.3%.2, meaningOne in Five Men Suffers from Androgenetic AlopeciaHow to “save” male pattern baldness? How to escape the predicament of “losing hair before finding a partner”? These have become the “existential questions” facing contemporary young and middle-aged men.
To gain a deeper understanding of the current status and diagnostic and treatment challenges of male hair loss in China, and to help men across the country address this “top priority,”Organon, a global leader in women’s health, recently announced that it will join forces with JD Health and the Chinese Non-Public Medical Institutions Association to launch the Comprehensive White Paper on Male Androgenetic Alopecia.This study will provide a “panoramic” profile of men with androgenetic alopecia in China by examining multiple dimensions, including population distribution, age characteristics, online shopping habits, and current diagnosis and treatment practices. Leveraging big data mining, it will also uncover the undermet needs of young people experiencing hair loss today.
Lin Yuwei, Head of the Marketing Department for Classic Brands at Organon China, stated:“As a global leader in healthcare, Organon boasts a portfolio of classic products well-recognized by patients and medical professionals alike. Androgenetic alopecia is a prevalent concern among contemporary men and represents a key area of Organon’s sustained commitment. Upholding our patient-first philosophy, we aim to provide greater value to patients through this comprehensive white paper on male androgenetic alopecia, helping them better understand the types and causes of hair loss, adopt scientifically grounded approaches, alleviate anxiety, and avoid common misconceptions.”
Shen Bin, Head of the Classic Brands Retail Division of Organon China, stated:“JD Health is a leading provider of healthcare products, services, and solutions in China, as well as a key partner of Organon. We have long collaborated with JD Health to drive innovation in the fields of chronic disease management and hair care. Leveraging JD Health’s service capabilities and accumulated experience in consumer health, we believe it can better illuminate the development context of the current market for androgenetic alopecia treatments, interpret consumer trends, and thereby support industry growth and innovation.”
Wang Yiting, General Manager of the Pharmaceutical Division at JD Health, stated:“In recent years, there has been a surge in user demand for hair loss-related products and services on JD Health. We have observed that consumers face significant confusion in determining their type and severity of hair loss, as well as in selecting appropriate products, thereby necessitating more professional online pharmaceutical care services. Through this white paper collaboration, we aim to better identify misconceptions and health needs among individuals experiencing hair loss, and leverage JD Health’s digital advantages alongside Organon’s advanced expertise in disease treatment to enhance public scientific understanding of hair loss issues.”
Hair loss is not merely a cosmetic concern; it also negatively impacts patients' quality of life and psychological well-being.A study involving 218 patients with androgenetic alopecia and alopecia areata indicated that hair loss generally has a moderate impact on quality of life, with 38.07% of patients experiencing a severe or greater impact.3。
Professor Wu Wenyu, Chairman of the Hair Medicine and Scalp Health Management Subcommittee under the Dermatology Professional Committee of the Chinese Non-Public Medical Institutions Association, stated:“Male pattern baldness is a progressively worsening condition, making early, standardized, and consistent treatment particularly crucial. To achieve better therapeutic outcomes, clinical guidelines recommend combination therapy with oral and topical medications.”However, many patients do not take hair loss seriously in its early stages, mistakenly believing that no treatment is necessary. Others attribute it to excessive sebum production or kidney deficiency, assuming that the condition can be reversed solely through oil control, dietary supplementation, or lifestyle modifications. Furthermore, some patients who do opt for pharmacological treatment are overly eager for rapid results; if they fail to see immediate effects, they may unauthorizedly discontinue medication or abort therapy, thereby greatly increasing the likelihood of treatment failure.
Therefore, the scientifically sound approach to managing hair loss is to seek medical attention promptly, consult qualified healthcare professionals at reputable hospitals, and, based on diagnostic findings, identify the underlying cause and administer targeted treatment.
Upholding its unwavering commitment to patients in China, Organon aims to be a pioneering practitioner of innovative pharmaceutical retail models in the country. It continuously expands collaborative partnerships across broader domains, dedicated to enhancing access to high-quality healthcare solutions.
In recent years, online consultations for hair loss prevention and regrowth, as well as the online purchase of related medications, have surged dramatically, making the internet a “new setting” for the diagnosis and treatment of hair loss. Since the beginning of this year, Organon has partnered with JD Health to jointly launch an online “Hair Care Center.” Leveraging the service capabilities accumulated over the past year by JD Pharmacy’s Single-Disease Care Center, and drawing on deep insights into younger user demographics, the initiative offers diverse and engaging educational content, providing an informative and entertaining “Guide to Hair Loss.”
It is reported that on the eve of JD.com’s 618 Shopping Festival in 2022, coinciding with the first anniversary of the launch of JD Pharmacy’s Single-Disease Care Center, JD Health announced comprehensive upgrades across four key areas: doctor-patient communication, free clinical consultations by physicians, health education, and health monitoring. These enhancements aim to provide users with more professional, convenient, and efficient one-stop pharmaceutical and healthcare services. Among its partners for the Hair Loss Care Center is Organon, which is committed to synchronizing patients with the latest global pharmacological treatment regimens and ensuring the provision of professional pharmaceutical care services.
In the future, leveraging digital technologies, the “Hair Care Center” jointly established by Organon and JD Health will launch a suite of convenient service toolkits, such as self-assessment tools for hair management. These tools will empower patients to gain a comprehensive understanding of their hair health, facilitating early detection and treatment of diseases and scientifically addressing androgenetic alopecia. Meanwhile, the initiative is committed to breaking down barriers between online internet-based consultations and disease self-management, thereby realizing a new model of end-to-end medical management that spans from physician care to medication and from diagnosis to solutions, ultimately enabling physicians to better support their patients.
06-2024-CN-NON-110170
For more information on diseases, please consult a healthcare professional.
References:
1 Hu Zhiqi, Miao Yong. Guidelines for the Diagnosis and Treatment of Androgenetic Alopecia in Chinese People[J]. Chinese Journal of Aesthetic and Plastic Surgery, 2019, 30(01):8-12.
2 Wang Tinglin, Shen Yiwei, Zhou Cheng, Wang Xiaoyan, Ding Xiaolan, Tian Shan, Liu Ying, Peng Guanghui, Xue Shuqi, Zhou Jun’e, Wang Renli, Meng Xuemei, Pei Guangde, Bai Yunhua, Liu Qing, Li Hang, Chen Jie, Cai Lin, Zhang Jianzhong. Epidemiological Survey of Androgenetic Alopecia in Six Provinces of China [J]. Journal of Clinical Dermatology, 2010, 39(12): 743-746.
3 Mao Yu, Dai Yeqin, Sun Chunqiu, et al. Investigation and analysis of quality of life and depression in patients with androgenetic alopecia and alopecia areata[J]. Chinese Journal of Dermatology, 2017, 50(5):4.